Brain Amyloid-Beta burden as per florbetaben (Neuraceq) pet and cognitive outcomes after deep brain stimulation in Parkinsin's disease

Fundació Clínic per la Recerca Biomèdica0 个研究点开始时间: 2016年7月15日最近更新: 2016年8月8日

适应症

试验速览

暂无简介。

•1.PD patients aged 60 to 69 years,
•2.Motor fluctuations refractory to the best medical treatment that have led to the indication of STN-DBS;
•3.Commitment to participate and complete all study procedures according to the principal investigator;
•4.Voluntary fulfilment and signature of the study Informed Consent Form.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 30

•1.Subjects not eligible for STN-DBS (due to presence of one or more exclusion criteria for STN-DBS including the possibility of a diagnosis different to PD, such as any of the atypical parkinsonisms) or likely not to be able to complete the study;
•2.PD-related dementia according to the MDS definition of PD-dementia;
•3.Any major disease or history of a major disease, especially hepatobilliar disease (AST /ALT = 5 x ULN) or advanced renal insufficiency (creatinine = 2 x ULN);
•4.Current or previous history of alcohol abuse or epilepsy;
•5.Allergy to FBB or any of its constituents;
•6.Multiple drug allergies and/or previous history of contrast allergy;
•7.Pregnancy or breast feeding or planned pregnancy during the study period;
•8.Any disease or history of disease which, in the opinion of the investigator, can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function);
•9.Evidence for any other neurological or psychiatric disease.

发起方

Fundació Clínic per la Recerca Biomèdica